Top Biotech Stocks To Add to Your Watchlist - November 15th

Key Points

• Moderna, Regeneron Pharmaceuticals, and Amgen were the biotech stocks highlighted by MarketBeat’s screener for having the sector’s highest recent dollar trading volumes. Biotech offers growth potential but carries risks tied to clinical trials, regulatory approvals, and research funding.
• In Friday trading, Moderna fell $7.98 to $223.37, Regeneron gained $4.28 to $955.47, and Amgen declined $1.39 to $465.67.
• The companies span different areas of medicine: Moderna focuses on mRNA vaccines and therapeutics, Regeneron develops treatments including EYLEA, and Amgen markets a broad portfolio of therapies for conditions ranging from osteoporosis to cancer.

Moderna, Regeneron Pharmaceuticals, and Amgen are the three Biotech stocks to watch today, according to MarketBeat's stock screener tool. Biotech stocks are shares of publicly traded companies that use biological science to develop products or services, such as medicines, vaccines, and diagnostic tests. For investors, they can offer growth potential but often carry substantial risk because a company’s prospects may depend on clinical-trial results, regulatory approvals, and research funding. These companies had the highest dollar trading volume of any Biotech stocks within the last several days.

Moderna (MRNA)

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.

Shares of Moderna stock traded down $7.98 on Friday, reaching $223.37. The company's stock had a trading volume of 8,041,048 shares, compared to its average volume of 15,522,397. Moderna has a 52 week low of $22.28 and a 52 week high of $280.80. The firm's fifty day simple moving average is $201.67 and its two-hundred day simple moving average is $96.41. The company has a quick ratio of 3.47, a current ratio of 3.62 and a debt-to-equity ratio of 0.52. The company has a market capitalization of $90.38 billion, a price-to-earnings ratio of -31.46 and a beta of 1.16.

Read Our Latest Research Report on MRNA

Regeneron Pharmaceuticals (REGN)

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

NASDAQ:REGN traded up $4.28 during mid-day trading on Friday, reaching $955.47. The company's stock had a trading volume of 1,165,612 shares, compared to its average volume of 984,019. Regeneron Pharmaceuticals has a 12-month low of $591.52 and a 12-month high of $991.73. The company has a current ratio of 3.35, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06. The firm's fifty day moving average price is $816.17 and its two-hundred day moving average price is $747.36. The stock has a market cap of $98.84 billion, a P/E ratio of 21.10, a PEG ratio of 1.26 and a beta of 0.10.

Read Our Latest Research Report on REGN

Amgen (AMGN)

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.

NASDAQ:AMGN traded down $1.39 during trading hours on Friday, reaching $465.67. The company had a trading volume of 2,122,101 shares, compared to its average volume of 2,720,013. The company has a current ratio of 1.48, a quick ratio of 1.20 and a debt-to-equity ratio of 3.60. Amgen has a 52 week low of $312.39 and a 52 week high of $483.99. The firm has a market cap of $251.89 billion, a price-to-earnings ratio of 27.01, a PEG ratio of 3.25 and a beta of 0.43. The firm's 50 day moving average price is $425.31 and its 200-day moving average price is $381.17.

Read Our Latest Research Report on AMGN

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.